Par Pharmaceutical Acquires Rights to Market and Distribute Generic Dexilant® in the U.S.
Par Pharmaceutical Companies, Inc. (NYSE: PRX) today announced that its Par Pharmaceutical, Inc. operating subsidiary has entered into an exclusive acquisition and license agreement with Handa Pharmaceuticals LLC to acquire Handa's ANDA for dexlansoprazole capsules, the generic version of Takeda's Dexilant®. Handa believes it is the first to file an ANDA containing a paragraph IV certification for the 60 mg strength of the product, which would potentially provide 180 days of marketing exclusivity. According to IMS Health data, annual sales in the U.S. for the 60 mg strength of Dexilant are approximately $517 million.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.